NNSCF yields 1.28% · JNJ yields 2.13%● Live data
📍 NNSCF pulled ahead of the other in Year 1
Combined, NNSCF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of NNSCF + JNJ for your $10,000?
NEC Networks & System Integration Corporation operates as a telecommunications infrastructure construction company in Japan and internationally. It operates through Digital Solutions Business, Network Infrastructures Business, and Engineering & Support Services Business segments. The Digital Solutions Business segment offers system integration services related to ICT platform and outsourcing/cloud services for business of enterprises and other customers, as well as solutions/services for customers' business transformation by using cutting-edge/digital technologies and contact center services. The Network Infrastructures Business segment provides system integration/services related to network infrastructures to telecom carriers, central and local governments, and social infrastructures service providers; and develops, manufactures, and sells network equipment. The Engineering & Support Services Business segment offers support services, such as maintenance and operations/monitoring related to ICT systems/services; and operations of company-wide service infrastructures. Its products include telephony servers, video conferencing systems, routers, switches, network testers, interface converters, load balancers, accelerators, Internet traffic, SSL-VPN access, firewalls, unauthorized access detection, authentication systems, operation and maintenance, spam blocking, physical security, log management, industry and task-specific applications, and software. NEC Networks & System Integration Corporation was incorporated in 1953 and is headquartered in Tokyo, Japan.
Full NNSCF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.